Ticker

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive…

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its…

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of…

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 30,205 call options on the stock. This represents an increase of 1,663% compared to the typical daily volume of 1,713 call options. Forte Biosciences Stock Performance NASDAQ: FBRX opened at $24.86 on Thursday. The stock has

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update. “The clinical development for FB102 continues to progress well with important readouts in 2026,” said Forte Biosciences CEO Paul Wagner, PhD. “The…